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Abstract 1 
Context: Metabolic syndrome (MetS) is a risk factor for cardiovascular disease (CVD) 2 
mortality. 3 
Objective: To evaluate the association of metabolic syndrome (MetS) with all-cause and 4 
cardiovascular mortality in apparently healthy young Korean subjects. 5 
Design: A retrospective study of 155,971 participants (mean age 41.8 years) in a health 6 
screening program, followed up for 3.7 years (597628.2 person-years). The risk for all-cause 7 
mortality and cardiovascular disease (CVD) mortality were analyzed according to the 8 
presence or absence of MetS.  9 
Main Outcomes: A total of 542 subjects died during follow-up. Women with MetS showed a 10 
significantly increased age-adjusted hazard ratio (HR) for all-cause mortality compared with 11 
women without MetS, even after adjustment for confounding factors (HR 1.82; 95% CI 1.15-12 
2.88). Subjects with MetS showed a significantly increased risk for CVD mortality compared 13 
with those without MetS, even after adjustment for confounding factors (HR 1.60; 95% CI 14 
1.02-2.20), of which significance disappeared when subjects with diabetes or hypertension at 15 
baseline were excluded from the analysis (HR 0.95; 95% CI 0.29-3.12).  16 
Conclusions: The presence of MetS increased the risk for all-cause mortality in women and 17 
the risk for CVD mortality in total population. These increased HR attributed to the pre-18 
existing diabetes or hypertension in this population.  19 
  20 
Introduction 1 
 2 
Metabolic syndrome (MetS) is a clustering of cardiometabolic risk factors (hyperglycemia, 3 
hypertension, dyslipidemia, and systemic inflammation) linked to insulin resistance and 4 
visceral obesity (1). The prevalence of metabolic syndrome varies from 5% to 41%, 5 
according to ethnic group. Since 1988, when Gerald Reaven first described MetS as 6 
“Syndrome X,” an abundance of research has been undertaken on its pathophysiology, 7 
prognosis, implications, therapeutic strategies, and clinical relationships with other metabolic 8 
diseases (2). 9 
Experts have focused on metabolic syndrome during the last few decades not only because 10 
of the increasing importance of obesity in the development of metabolic diseases but also 11 
because of the impact of MetS on mortality and the development of cardiovascular diseases 12 
(3,4). The presence of metabolic syndrome is associated with increased risk of diabetes the 13 
risk of diabetes by two-fold, coronary artery disease by two- to three-fold, and ischemic 14 
stroke by two-fold. MetS increases the risk for other metabolic diseases as well (1,4). There 15 
are conflicting data on the association between metabolic syndrome and mortality, with some 16 
studies showing an increase in mortality (3-7) and others showing no increase in mortality 17 
(8,9). 18 
The definition of MetS has evolved during the three decades since the first description of 19 
“Syndrome X” by Reaven (2). MetS has been defined by taking into account insulin 20 
resistance, central obesity, and atherosclerosis (10). In 2009, members from the International 21 
Diabetes Federation; National Heart, Lung, and Blood Institute; the American Heart 22 
Association; the World Heart Federation; the International Atherosclerosis Society and the 23 
International Association for the Study of Obesity produced a harmonized definition of MetS 24 
(11). In this definition, three abnormal findings out of five previously used components of 25 
MetS qualify a person for MetS, with population- and country-specific definitions for waist 1 
circumference. 2 
Most of the previously published studies that have investigated the relationships between 3 
MetS and mortality have been undertaken with subjects with a history of diabetes or 4 
hypertension included in the study population, since diabetes and hypertension qualify as 5 
individual components of the MetS definition. However, diabetes and hypertension may also 6 
be considered outcomes or endpoints of MetS (11). In addition, few studies have been 7 
performed on the association of MetS and mortality in Asian people. Therefore, we analyzed 8 
the all-cause and CVD mortality rates attributable to MetS before and after excluding 9 
subjects with diabetes or hypertension in a large number of Korean adults without previous 10 
history of CVD followed up with for a median of 3.7 years. 11 
  12 
Subjects and Methods 1 
Study population 2 
The study population consisted of examinees who participated in a comprehensive health 3 
screening program at Kangbuk Samsung Hospital, Seoul, Korea (Kangbuk Samsung Health 4 
Study), from 2002 to 2009 (N=278,528). The purpose of the screening program was to 5 
promote health through early detection of chronic diseases and their risk factors. Additionally, 6 
in Korea, the Industrial Safety and Health Law requires employees to participate in annual or 7 
biennial health examinations. About 60% of the participants were employees of various 8 
companies and local governmental organizations and their spouses, with the remaining 9 
participants registering individually for the program. 10 
For this analysis, 119,347 were excluded for one or more of the following reasons: 136 11 
subjects with missing data on metabolic syndrome components; 2,627 subjects with histories 12 
of malignancy; 97 subjects with history of coronary heart disease or ischemic stroke; 11 13 
subjects with unknown vital status; and 116,605 subjects without waist circumference at 14 
baseline. As some individuals met more than one criterion for exclusion, the total number of 15 
eligible subjects for the study was 159,971. Further analyses were undertaken after excluding 16 
subjects with diabetes (n=7,292) and subjects with diabetes or hypertension (n=34,152). 17 
This study was approved by the Institutional Review Board of Kangbuk Samsung Hospital, 18 
which exempted the requirement for informed consent, as we only accessed data 19 
retrospectively that was de-identified. 20 
Mortality follow-up between January 1, 2002, and December 31, 2009, was based on the 21 
nationwide death certificate data of the Korea National Statistical Office. Deaths among 22 
subjects were confirmed by matching the information to death records. Death certificates 23 
from the National Statistical Office were identified with the use of identification numbers 1 
assigned to subjects at birth. Abstractors coded the causes of death according to the 2 
International Classification of Diseases, 10
th
 revision. 3 
 4 
Anthropometric and laboratory measurements 5 
Data on medical history, medication use, and health-related behaviors were collected 6 
through a self-administered questionnaire, while the physical measurements and serum 7 
biochemical parameters were measured by trained staff, all collected during the health 8 
examinations. Details regarding alcohol use included the frequency of intake per week and 9 
the average amount of intake per episode. Current smokers were identified and the weekly 10 
frequency of moderate- or vigorous-intensity physical activity assessed. Body weight was 11 
measured in light clothing and no shoes to the nearest 0.1 kilogram using a digital scale. 12 
Height was measured to the nearest 0.1 centimeter. Body mass index (BMI) was calculated as 13 
weight in kilograms divided by height in meters squared. Trained nurses measured sitting 14 
blood pressure with standard mercury sphygmomanometers. The waist circumference (WC) 15 
was measured in the standing position, at the middle point between anterior iliac crest and 16 
lower border of rib by a single examiner. 17 
Blood specimens were sampled from the antecubital vein after more than 12 hours of fasting. 18 
Serum levels of glucose, uric acid, total cholesterol, triglycerides, low-density lipoprotein 19 
(LDL) cholesterol, and high-density lipoprotein cholesterol (HDL-C) were measured using 20 
Bayer Reagent Packs (Bayer Diagnostics, Leverkusen, Germany) on an automated chemistry 21 
analyzer (Advia 1650 Autoanalyzer; Bayer Diagnostics, Leverkusen, Germany). 22 
 23 
Definitions of metabolic parameters 1 
Hypertension was defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure 2 
≥90 mm Hg, self-report history of hypertension, or current use of antihypertensive 3 
medication (12). Diabetes mellitus was defined as a fasting serum glucose level ≥126 mg/dL, 4 
a self-reported history of diabetes, or current use of diabetic medication (13).  5 
MetS was defined based on the „harmonized criteria‟ by the related federations (11). The 6 
cutoffs for the presence of abdominal obesity is defined as a WC ≥90 cm for men and ≥85 cm 7 
for women in Korea by ethnicity-specific cutoff (14) 8 
 9 
Statistical analysis 10 
The χ2-test and Student‟s t-test were used to compare the characteristics of the study 11 
participants at baseline between alive and dead. The distribution of continuous variables was 12 
evaluated and the appropriate transformations were undertaken during analysis, as needed. 13 
We used Cox proportional hazards models to estimate adjusted hazard ratios (HRs) and 95% 14 
confidence intervals for mortality, comparing subjects with or without MetS, according to 15 
number of MetS components. The models were initially adjusted for age and sex, then for 16 
smoking status, alcohol intake, and regular exercise. Additional step-wise regression analyses 17 
with individual components of metabolic syndrome included in the model were performed as 18 
crude, and after adjustment for confounding variables. For testing linear risk trends, we used 19 
the number of categories as a continuous variable in the regression models. We checked the 20 
proportional hazards assumption by examining graphs of estimated log (-log) survival. 21 
The statistical analysis was performed using STATA version 11.2 (StataCorp LP, College 22 
Station, TX, USA). All reported P values are two tailed, and P value <0.05 was considered 1 
statistically significant. 2 
  3 
Results 1 
Mean age of total study population was 41.8 years with 597628.3 person-years and mean 2 
BMI was 23.5 kg/m
2
.
 
General characteristics of the participants at baseline are presented in 3 
Table 1. The proportion of subjects with MetS at baseline was 12.6%. 4 
 5 
Risks for all-cause mortality according to presence or absence of MetS  6 
During the median follow-up period of 3.7±2.2 years, 542 subjects died. When HR for all-7 
cause mortality was analyzed, subjects with MetS did not show significantly increased HR 8 
compared with those without MetS (HR 1.19; 95% CI 0.98-1.46). When the analyses were 9 
performed separately for each sex, men did not show an increased HR for all-cause mortality 10 
in subjects with MetS (Table 2). In contrast, women showed significantly increased age-11 
adjusted and multivariate HR for all-cause mortality (HR 1.82; 95% CI 1.15-2.88) (Table 2). 12 
When these analyses were performed after exclusion of subjects with diabetes or 13 
hypertension from the study population, there were no significant increases in HRs in either 14 
gender (Table 2). 15 
 16 
Risks for all-cause mortality according to the number of MetS components  17 
When risks for all-cause mortality were analyzed according to the number of MetS 18 
components at baseline, HR did not show any increasing trend from one to five components 19 
of MetS (Tab1e 3). Men did not show a significantly increased HR for all-cause mortality, 20 
while women showed a trend for increased HR for all-cause mortality as the number of MetS 21 
components increased (Table 3). When subjects with diabetes or hypertension at baseline 22 
were excluded from the analyses, these results became non-significant. 1 
 2 
Risks for cardiovascular mortality according to presence or absence of MetS  3 
When risks for CVD mortality were analyzed according to the presence of absence of MetS, 4 
subjects with MetS showed significantly increased HR of 1.60 (95% CI 1.02-2.20) compared 5 
with subjects without MetS in the multivariate model (Table 4). Men showed a significantly 6 
increased multivariate HR for CVD mortality, while women did not show a significantly 7 
increased risk for CVD mortality. As observed for all-cause mortality, when subjects with 8 
diabetes or hypertension were excluded from the analyses, these HRs were not significantly 9 
different from subjects without MetS. 10 
 11 
Risks for cardiovascular mortality according to the number of MetS components  12 
When risks for CVD mortality were analyzed according to the number of MetS components 13 
at baseline, the HR linearly increased from 1.99 with one component of MetS to 2.98 in 14 
subjects with equal to or more than four components of MetS in the multivariate model 15 
(Table 5). Men showed a significant linear increase in the HR as the number of MetS 16 
components increased, whilst women did not (Table 5). When subjects with diabetes or 17 
hypertension were excluded from the analyses, the HRs were not significantly different from 18 
subjects without MetS. 19 
 20 
Risks for all-cause mortality according to the individual components of MetS at baseline 21 
When risks for all-cause mortality were analyzed according to the individual components of 22 
MetS, the presence of high fasting blood glucose showed the highest HR among the 1 
individual components (HR 1.40; 95% CI 1.16-1.69) (Table 6). In stepwise multivariate 2 
model, the presence of high fasting blood glucose or high blood pressure showed 3 
significantly increased HRs for all-cause mortality (Table 6). However, when subjects with 4 
diabetes were excluded from the population, presence of high blood pressure and low 5 
triglyceride (TG) showed increased HRs for all-cause mortality. When subjects with diabetes 6 
or hypertension were excluded from the population, only presence of low TG level showed 7 
significantly increased HR for all-cause mortality, although this significance disappeared in 8 
multivariate model (Table 6). 9 
 10 
Risks for CVD mortality according to the individual components of MetS at baseline 11 
When risks for CVD mortality were analyzed according to the individual components of 12 
MetS, the presence of high blood pressure showed the highest HR among the individual 13 
components (HR 2.87; 95% CI 1.83-4.50) (Table 7). In stepwise multivariate model, only the 14 
presence of high blood pressure showed significantly increased HR for CVD mortality (Table 15 
7). When subjects with diabetes were excluded from the population, only the presence of high 16 
blood pressure showed significantly increased HR for CVD mortality, which was consistently 17 
significant in stepwise multivariate model. When subjects with diabetes or hypertension were 18 
excluded from the population, none of the individual components showed significantly 19 
increased HR for CVD mortality (Table 7). 20 
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Discussion 1 
In this study, our results show that, in a large number of Koreans participating in a health 2 
screening program followed for a median of 3.7 years, risks for all-cause mortality increased 3 
in women with MetS compared with those without MetS. However, these significant 4 
increases in HR disappeared when subjects with diabetes or hypertension were excluded from 5 
the study. For CVD mortality, HR was significantly increased in subjects with MetS even 6 
after adjustment for confounding variables, but the increased hazard was markedly attenuated 7 
after excluding subjects with diabetes or hypertension. The presence of individual 8 
components of MetS increased the HR for all-cause and CVD mortality, which disappeared 9 
after exclusion of subjects with diabetes or hypertension from the analyses. These results 10 
suggest that it is pre-existing diabetes or hypertension that largely accounts for the increased 11 
all-cause and CVD mortality attributable to MetS. 12 
MetS is a cluster of risk factors for cardiometabolic diseases comprising abdominal obesity, 13 
hyperglycemia, high blood pressure, high TG, and low HDL-C (1). Numerous definitions of 14 
MetS have been proposed and many studies have been published regarding the clinical 15 
implications of MetS for metabolic or cardiovascular diseases. The main pathophysiological 16 
mechanism that has been proposed for how MetS contributes to these diseases involves 17 
insulin resistance, caused by accumulation of visceral fat. Overall, MetS is known to cause an 18 
approximately two-fold increase in risk of CVD over 5 to 10 years, and at least a five-fold 19 
increase in the development of diabetes (1). Importantly in the context of our findings, in the 20 
„harmonized definition of MetS recommended in 2009, the presence of diabetes or 21 
hypertension is included as one of the component features of the syndrome (11). 22 
In this study, the presence of MetS increased the HR for all-cause in women and CVD 23 
mortality by 1.6- to 1.9-fold, but this increase in HR was attenuated, when subjects with 24 
diabetes or hypertension were excluded from the analyses. Previously published studies show 1 
inconsistent results regarding the association between MetS and mortality, with some studies 2 
showing significantly increased risks for mortality in subjects with MetS (3-7) and others 3 
showing no increase in mortality in those with MetS (8,9). However, some of these studies 4 
included subjects with diabetes as a MetS criterion (5,6,8), while other studies excluded 5 
subjects with diabetes from the analyses (4,7,9). In a study by Ford et al. (8), which analyzed 6 
the risk for mortality in subjects with MetS, subjects with diabetes at baseline were excluded. 7 
The authors found that the presence of MetS was not associated with increased all-cause or 8 
CVD mortality. However, in a few studies, the presence of MetS was associated with an 9 
increased risk of mortality after exclusion of subjects with diabetes at baseline (4,7), which is 10 
in contrast to the results of our study. These data and our results suggest that the definition of 11 
MetS markedly affects the mortality risk, since diabetes per se increases the risk of CVD (15).  12 
When the risks for all-cause and CVD mortality were analyzed according to the presence of 13 
individual components of MetS, the presence of high blood pressure showed consistently 14 
increased HRs for all-cause and CVD mortality in multivariate model. These significant 15 
effect of high blood pressure on increased mortality in subjects with MetS was consistent 16 
even after excluding subjects with diabetes. These results suggest relatively more important 17 
contribution of high blood pressure on increased mortality in subjects with MetS compared 18 
with other components of MetS. However, these effects disappeared after excluding subjects 19 
with hypertension from the model, meaning that the increased HR for mortality by the 20 
presence of MetS attributes largely to the effect of pre-existing hypertension.       21 
There have been few studies investigating the association between MetS and mortality risk 22 
in Asian subjects. In a study of 25,471 Japanese men, MetS was associated with an increased 23 
risk of all-cause death with an HR of 4.88 (7). In that study, the investigators excluded 24 
subjects with diabetes, hypertension, or CVD from the analyses, similar to our study, and they 1 
still showed an increased risk for mortality. Therefore, the discrepancy between our study 2 
data and the results of previous studies are not likely to be due to ethnic differences between 3 
Asians and people of white European ethnicity. 4 
Our study has limitations. It was performed in a relatively homogenous population of 5 
working individuals who participated in a health screening program, and is not fully 6 
representative of the whole Korean population. In addition, our study was not an actually 7 
prospective or randomized controlled study, but was a longitudinal, observational study 8 
analyzed from a retrospective data. Therefore, direct cause-and-effect relationship could not 9 
be drawn from our study. However, the number of subjects included in our study is larger 10 
than in any previous studies investigating this question (4). Despite these limitations, our 11 
results give meaningful information to the literature regarding the association of increased 12 
mortality in Asian subjects with MetS.  13 
We observed an increased risk for all-cause and CVD mortality in subjects with MetS with a 14 
median follow-up of 3.7 years in this large group of Korean adults without previous history 15 
of CVD. However, these increased HRs were attenuated after exclusion of subjects with 16 
diabetes or hypertension from the study population. These results suggest that it is diabetes or  17 
hypertension that largely accounts for the increased CVD mortality attributed to MetS.  18 
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Table 1. General characteristics of the participants at baseline 1 
Characteristics (n=159,971) Alive (n=159,429) Dead (n=542) P value 
Total population (%) 159,429 (99.7) 542 (0.3)  
Male (n=88,809) 88,395(55.4) 414 (76.4) <0.001 
Female (n=71,162) 71,034 (44.6) 128 (23.6)  
Age (years)  41.7 (10.1) 53.4 (13.0) <0.001 
BMI 23.5 (3.1) 23.8 (3.1) 0.0231 
Waist circumference (cm) 79.8 (9.5) 83.4 (9.1) <0.001 
Systolic BP (mmHg) 115.0 (15.0) 124.6 (19.1) <0.001 
Diastolic BP (mmHg)  75.0(10.1) 79.1(11.8) <0.001 
Fasting blood glucose (mg/dl) 94.7 (17.7) 105.5 (34.0) <0.001 
Total cholesterol (mg/dl)  194.9 (34.8) 200.5 (40.6) 0.0002 
LDL-C (mg/dl) 113.4 (30.0) 117.0 (34.0) 0.0060 
HDL-C (mg/dl)  55.7 (12.7) 55.2 (14.4) 0.3604 
Triglycerides (mg/dl)  105(73-155) 119(87-169) <0.001 
Smoking status (%)   <0.001 
Never smoker, n=147,502 87,589 (55.9) 190 (36.2)  
Former smoker, n=45,921 27,443 (17.5) 133 (25.3)  
Current smoker, n=77,361 41,560 (26.5) 202 (38.5)  
Alcohol drinking status (%)   <0.001 
No alcohol intake (0g/day), n=107,337  62,302 (40.0) 203 (38.8)  
Alcohol intake (10g/day), n=123,561 70,497 (45.2) 197 (37.7)  
Alcohol intake (20g/day), n=36,983 23,063 (14.8) 123 (23.5)  
Metabolic syndrome (%) 19,969 (12.5) 134 (24.7) <0.001 
Regular exercise (%)
a 28,828 (18.3) 96 (18.1) 0.922 
Education
b
 60,638 (70.2) 198 (48.2) <0.001 
History of hypertension (%)  14,167 (8.9) 117 (21.6) <0.001 
History of diabetes (%)  4,618 (2.9) 76 (14.0) <0.001 
Diabetes (%)
†
  7,191 (4.5) 101 (18.6) 0.976 
Hypertension (%)  30,170 (18.9) 226 (41.7) <0.001 
Data are presented with mean (standard deviation), median (interquartile range), or percentage. 1 
a
 ≥ 1 time per week, †Based on fasting blood glucose, history and medication use 2 
BP, blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol 3 
b ≥ college graduate 4 
 5 
  6 
Table 2. Risks for all-cause mortality according to presence or absence of metabolic syndrome at 1 
baseline 2 
Metabolic 
syndrome 
Number of 
subjects 
Person-years 
Number 
of events 
Incidence Density 
(10000 person-year) 
Age-adjusted 
HR (95% CI) 
Multivariate HRa 
(95% CI) 
In all subjects 
Total  155,971      
MetS – 139,868 523,095.0 408 7.8 1.00 (reference) 1.00 (reference) 
MetS + 20,103 74,533.3 134 18.0 1.19 (0.98-1.46) 1.15 (0.94-1.42) 
       
Men  88,809      
MetS – 74,237 277,023.8 315 11.1 1.00 (reference) 1.00 (reference) 
MetS + 14,572 71,095.4 99 14.9 1.08 (0.86-1.36) 1.06 (0.84-1.35) 
       
Women  71,162      
MetS – 65,631 226,504.9 93 4.0 1.00 (reference) 1.00 (reference) 
MetS + 5,531 23,004.1 35 16.5 1.89 (1.24-2.89) 1.82 (1.15-2.88) 
 
After excluding subjects with DM, HTN  
Total  125,819      
MetS – 118,534 430,562.4 258 5.9 1.00 (reference) 1.00 (reference) 
MetS + 7,285 35,966.6 22 7.2 0.92 (0.60-1.43) 0.89 (0.57-1.40) 
       
Men  65,422      
MetS – 60,035 236,422.0 194 8.2 1.00 (reference) 1.00 (reference) 
MetS + 5,387 19,488.0 15 7.7 0.78 (0.46-1.31) 0.77 (0.46-1.31) 
       
Women  60,397      
MetS – 58,499 204,612.1 64 3.1 1.00 (reference) 1.00 (reference) 
MetS + 1,898 6,006.9 7 11.7 1.88 (0.84-4.25) 1.80 (0.75-4.33) 
a Adjusted for age, sex, smoking status, alcohol intake, regular exercise 3 
HR, hazard ratio; CI, confidence interval; MetS, metabolic syndrome; DM, diabetes mellitus; HTN, hypertension 4 
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Table 3. Risks for all-cause mortality according to the number of metabolic syndrome components at 1 
baseline 2 
Number of 
MetS 
components 
Number of 
subjects 
Person-years Number 
of events 
Incidence Density 
(10000 person-
year) 
Age-adjusted 
HR (95% CI) 
Multivariate 
HRa (95% CI) 
In all subjects 
Total  159,971      
0  66,355 244,697.9 131 5.4 1.00 (reference) 1.00 (reference) 
1  45,682 172,987.6 142 8.2 0.93 (0.73-1.19) 0.93 (0.73-1.19) 
2  27,931 105,409.4 135 12.8 1.04 (0.81-1.34) 1.03 (0.80-1.33) 
3  14,258 53,418.2 95 17.8 1.22 (0.92-1.60) 1.18 (0.89-1.57) 
4  5,127 18,685.3 34 18.2 1.10 (0.75-1.61) 1.04 (0.70-1.56) 
5  718 2,429.8 5 20.6 1.16 (0.47-2.85) 0.93 (0.34-2.52) 
P for 
trend 
    0.144 0.308 
Men  88,809      
0 27,503 108,024.6 92 8.5 1.00 (reference) 1.00 (reference) 
1 27,077 107,572.4 112 10.4 0.91 (0.69-1.20) 0.90 (0.68-1.20) 
2 19,657 7,6847.8 111 14.4 1.02 (0.77-1.35) 1.00 (0.75-1.33) 
3 10,457 40,412.2 68 16.8 1.03 (0.75-1.42) 1.01 (0.73-1.40) 
4 3,712 13,901.8 26 18.7 1.02 (0.66-1.59) 1.01 (0.64-1.58) 
5 403 1,360.4 5 36.8 1.75 (0.71-4.32) 1.38 (0.50-3.77) 
P for 
trend 
    0.458 0.618 
Women  71,162      
0 38,852 136,673.3 39 2.9 1.00 (reference) 1.00 (reference) 
1 18,605 65,415.2 30 4.6 1.08 (0.66-1.75) 1.15 (0.69-1.91) 
2 8,174 28,561.7 24 8.4 1.30 (0.75-2.25) 1.38 (0.77-2.45) 
3 3,801 13,005.9 27 20.8 2.51 (1.44-4.37) 2.60 (1.45-4.69) 
4 1,415 4,783.5 8 16.7 1.71 (0.76-3.87) 1.53 (0.61-3.83) 
5 315 1,069.5 0 0 - - 
P for 
trend 
    0.022 0.038 
 
After excluding subjects with DM, HTN  
Total  125,819      
0 64,821 240,065.4 124 5.2 1.00 (reference) 1.00 (reference) 
1 36,769 138,172.6 80 5.8 0.79 (0.60-1.05) 0.80 (0.60-1.07) 
2 16,944 62,796.1 54 8.6 0.94 (0.68-1.30) 0.92 (0.66-1.29) 
3 5,925 20,948.4 18 8.6 0.85 (0.52-1.40) 0.82 (0.49-1.36) 
4 1,256 4,237.7 4 9.4 0.84 (0.31-2.28) 0.84 (0.31-2.29) 
5 104 308.8 0 0 - - 
P for 
trend 
    0.416 0.353 
Men  65,422      
0 26,698 105,743.0 86 8.1 1.00 (reference) 1.00 (reference) 
1 21,354 84,701.1 63 7.4 0.80 (0.58-1.10) 0.79 (0.57-1.11) 
2 11,983 45,977.9 45 9.8 0.94 (0.66-1.36) 0.91 (0.62-1.31) 
3 4,377 16,027.6 12 7.5 0.70 (0.38-1.28) 0.69 (0.37-1.26) 
4 943 3,268.8 3 9.2 0.78 (0.25-2.48) 0.76 (0.24-2.42) 
5 67 191.6 0 0 - - 
P for 
trend 
    0.296 0.234 
Women  60,397      
0 38,123 134,322.4 38 2.8 1.00 (reference) 1.00 (reference) 
1 15,415 53,471.5 17 3.2 0.86 (0.48-1.53) 0.92 (0.50-1.68) 
2 4,961 16,818.2 9 5.4 1.07 (0.50-2.29) 1.24 (0.58-2.67) 
3 1,548 4,920.8 6 12.2 1.97 (0.80-4.88) 1.93 (0.72-5.17) 
4 
313 968.9 1 10.3 
1.39 (0.18-
10.41) 
1.70 (0.23-12.84) 
5 37 117.2 0 0 - - 
P for 
trend 
    0.388 0.296 
a Adjusted for age, sex, smoking status, alcohol intake, regular exercise 1 
MetS, metabolic syndrome; HR, hazard ratio; CI, confidence interval; MetS, metabolic syndrome; DM, diabetes mellitus; 2 
HTN, hypertension; 3 
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Table 4. Risks for cardiovascular mortality according to presence or absence of metabolic syndrome 1 
at baseline 2 
Metabolic 
syndrome 
Number of 
subjects 
Person-years Number 
of events 
Incidence Density 
(10000 person-
year) 
Age-adjusted 
HR (95% CI) 
Multivariate 
HRa (95% CI) 
In all subjects 
Total  155,971      
MetS - 139,868 523,095.0 69 1.3 1.00 (reference) 1.00 (reference) 
MetS + 20,103 74,533.3 31 4.2 1.63 (1.06-2.52) 1.60 (1.02-2.20) 
       
Men  88,809      
MetS - 74,237 292,444.8 52 1.8 1.00 (reference) 1.00 (reference) 
MetS + 14,572 55,674.3 26 4.7 1.73 (1.07-2.78) 1.67 (1.02-2.72) 
       
Women  71,162      
MetS - 65,631 230,650.2 17 0.7 1.00 (reference) 1.00 (reference) 
MetS + 5,531 18,858.9 5 2.7 1.32 (0.45-3.84) 1.38 (0.42-4.57) 
 
After excluding subjects with DM, HTN  
Total  125,819      
MetS - 118,534 441,034.1 34 0.8 1.00 (reference) 1.00 (reference) 
MetS + 7,285 25,494.9 3 1.2 0.99 (0.30-3.25) 0.95 (0.29-3.12) 
       
Men  65,422      
MetS - 60,035 23,6422.0 25 1.1 1.00 (reference) 1.00 (reference) 
MetS + 5,387 19,488.0 3 1.5 1.22 (0.37-4.04) 1.14 (0.34-3.78) 
       
Women  60,397      
MetS - 58,499 204,612.1 9 0.4 1.00 (reference) 1.00 (reference) 
MetS + 1,898 6,006.9 0 0 - - 
a Adjusted for age, sex, smoking status, alcohol intake, regular exercise 3 
HR, hazard ratio; CI, confidence interval; MetS, metabolic syndrome; DM, diabetes mellitus; HTN, hypertension;  4 
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Table 5. Risks for cardiovascular mortality according to the number of metabolic syndrome 1 
components at baseline 2 
Number of 
MetS 
components 
Number of 
subjects 
Person-years Number 
of events 
Incidence 
Density (10000 
person-year) 
Age-adjusted HR 
(95% CI) 
Multivariate 
HRa (95% CI) 
In all subjects 
Total  159,971      
0 66,355 244,697.9 12 0.5 1.00 (reference) 1.00 (reference) 
1 45,682 172,987.6 29 1.7 2.14 (1.08-4.22) 1.99 (1.00-3.95) 
2 27,931 105,409.4 28 2.7 2.47 (1.23-4.93) 2.28 (1.13-4.60) 
3 14,258 53,418.2 22 4.1 3.24 (1.57-6.68) 2.88 (1.37-6.03) 
4 5,127 18,685.3 8 4.3 2.98 (1.19-7.46) 2.98 (1.19-7.46) 
5 718 2,429.8 1 4.1 2.73 (0.35-21.25) 2.65 (0.34-20.70) 
P for 
trend 
    0.002 0.004 
Men  88,809      
0 27,503 108,024.6 8 0.7 1.00 (reference) 1.00 (reference) 
1 27,077 107,572.4 19 1.8 1.82 (0.80-4.18) 1.71 (0.74-3.95) 
2 19,657 76,847.8 25 3.3 2.74 (1.22-6.13) 2.59 (1.15-5.82) 
3 10,457 40,412.2 18 4.5 3.29 (1.41-7.65) 2.96 (1.26-6.98) 
4 3,712 13,901.8 7 5.0 3.31 (1.18-9.25) 3.22 (1.15-9.04) 
5 403 1,360.4 1 7.4 4.22 (0.52-34.09) 4.02 (0.50-32.54) 
P for 
trend 
 
   0.001 0.003 
Women  71,162      
0 38,852 136,673.3 4 0.3 1.00 (reference) 1.00 (reference) 
1 18,605 65,415.2 10 1.5 3.34 (1.01-11.01) 3.32 (0.99-11.14) 
2 8,174 28,561.7 3 1.1 1.45 (0.30-7.03) 1.11 (0.19-6.59) 
3 3,801 13,005.9 4 3.1 3.26 (0.72-14.86) 2.94 (0.57-15.23) 
4 1,415 4,783.5 1 2.1 1.86 (0.19-18.44) 2.34 (0.23-23.78) 
5 315 1,069.5 0 0 - - 
P for 
trend 
 
   0.550 0.548 
 
After excluding subjects with DM, HTN  
Total  125,819      
0 64,821 240,065.4 12 0.5 1.00 (reference) 1.00 (reference) 
1 36,769 138,172.6 13 0.9 1.39 (0.63-3.07) 1.37 (0.62-3.03) 
2 16,944 62,796.1 9 1.4 1.74 (0.72-4.20) 1.69 (0.70-4.08) 
3 5,925 20,948.4 2 1.0 1.06 (0.23-4.80) 1.02 (0.22-4.61) 
4 1,256 4,237.7 1 2.4 2.42 (0.31-18.83) 2.24 (0.29-17.52) 
5 104 308.8 0 0 - - 
P for 
trend 
 
   0.325 0.381 
Men  65,422      
0 26,698 105,743.0 8 0.8 1.00 (reference) 1.00 (reference) 
1 21,354 84,701.1 9 1.1 1.25 (0.48-3.24) 1.21 (0.47-3.15) 
2 11,983 45,977.9 8 1.7 1.88 (0.70-5.02) 1.77 (0.66-4.75) 
3 4,377 16,027.6 2 1.2 1.28 (0.27-6.07) 1.19 (0.25-5.63) 
4 943 3,268.8 1 3.1 2.94 (0.37-23.62) 2.56 (0.32-20.71) 
5 67 191.6 0 0 - - 
P for 
trend 
 
   0.236 0.311 
Women  60,397      
0 38,123 134,322.4 4 0.3 1.00 (reference) 1.00 (reference) 
1 15,415 53,471.5 4 0.7 2.00 (0.48-8.26) 2.10 (0.51-8.64) 
2 4,961 16,818.2 1 0.6 1.23 (0.13-11.91) 1.29 (0.13-12.44) 
3 1,548 4,920.8 0 0 - - 
4 313 968.9 0 0 - - 
5 37 117.2 0 0 - - 
P for 
trend 
 
   0.992 0.942 
a Adjusted for age, sex, smoking status, alcohol intake, regular exercise 1 
HR, hazard ratio; CI, confidence interval; MetS, metabolic syndrome; DM, diabetes mellitus; HTN, hypertension;  2 
Table 6. Risks for all-cause mortality according to metabolic syndrome components at baseline 1 
 In all subjects After excluding subjects with DM After excluding subjects with DM, HTN 
Components of metabolic syndrome full-adjusted HR 
(95% CI) 
Stepwise HRa 
(95% CI) 
full-adjusted HR 
(95% CI) 
Stepwise HRa  
(95% CI) 
full-adjusted HR 
(95% CI) 
Stepwise HRa     
(95% CI) 
Total  N=155,971  N=152,679  N=125,819  
   Fasting blood glucose 1.40 (1.16-1.69) 1.41 (1.17-1.70) 1.13 (0.91-1.42) - 1.07 (0.80-1.45) - 
   Blood pressure 1.27 (1.05-1.53) 1.28 (1.06-1.54) 1.29 (1.04-1.59) 1.30 (1.05-1.60) 1.34 (0.97-1.86) - 
Triglyceride 0.65 (0.53-0.79) 0.65 (0.54-0.79) 0.67 (0.53-0.83) 0.67 (0.54-0.83) 0.65 (0.48-0.87) - 
High-density lipoprotein cholesterol  1.06 (0.81-1.37) - 0.94 (0.69-1.29) - 1.14 (0.78-1.65) - 
Waist circumference 1.05 (0.85-1.28) - 1.06 (0.84-1.33) - 0.91 (0.65-1.26) - 
Men  N=87,261  N=82,342  N=64,358  
Fasting blood glucose 1.32 (1.07-1.63) 1.32 (1.07-1.63) 1.05 (0.82-1.35)  0.96 (0.69-1.35)  
Blood pressure 1.24 (1.01-1.53) 1.24 (1.01-1.53) 1.19 (0.94-1.51) - 1.29 (0.89-1.85) - 
Triglyceride 0.68 (0.55-0.84) 0.68(0.55-0.84) 0.68 (0.54-0.87) - 0.67 (0.49-0.92) - 
High-density lipoprotein cholesterol 1.04 (0.74-1.45) - 0.93 (0.62-1.39) - 1.28 (0.81-2.03) - 
Waist circumference 1.02 (0.81-1.28) - 1.05 (0.81-1.36) - 0.86 (0.60-1.24) - 
Women  N=67,299  N=65,266  N=57,488  
Fasting blood glucose 1.77 (1.17-2.68) 1.85 (1.24-2.77) 1.51 (0.94-2.39)  1.62 (0.87-3.01)  
Blood pressure 1.46 (0.95-2.23) - 1.83 (1.16-2.88) 1.81 (1.15-2.83) 1.67 (0.80-3.48) - 
Triglyceride 0.59 (0.36-0.97) - 0.68 (0.39-1.16) - 0.67 (0.31-1.45) - 
High-density lipoprotein cholesterol 1.13 (0.73-1.74) - 1.02 (0.63-1.66) - 1.00 (0.53-1.86) - 
Waist circumference 1.28 (0.80-2.04) - 1.20 (0.71-2.03) - 1.27 (0.60-2.71) - 
a Adjusted for age, sex, smoking status, alcohol intake, regular exercise 2 
HR, hazard ratio; CI, confidence interval; DM, diabetes mellitus; HTN, hypertension; CVD, cardiovascular disease 3 
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Table 7. Risks for cardiovascular mortality according to metabolic syndrome components at baseline 1 
 In all subjects After excluding subjects with DM After excluding subjects with DM, HTN 
Components of metabolic syndrome full-adjusted HR 
(95% CI) 
Stepwise HRa  
(95% CI) 
full-adjusted HR 
(95% CI) 
Stepwise HRa   
(95% CI) 
full-adjusted HR 
(95% CI) 
Stepwise HRa  
(95% CI) 
Total  N=155,971  N=152,679  N=125,819  
Fasting blood glucose 0.94 (0.61-1.47)  0.76 (0.45-1.30)  0.85 (0.37-1.98)  
Blood pressure 2.87 (1.83-4.50) 2.90 (1.86-4.52) 3.17 (1.95-5.15) 3.20 (1.98-5.16) 1.92 (0.85-4.30) - 
Triglyceride 0.90 (0.58-1.38) - 0.87 (0.54-1.40) - 0.93 (0.45-1.94) - 
High-density lipoprotein cholesterol 1.16 (0.64-2.10) - 1.23 (0.65-2.34) - 2.13 (0.93-4.85) - 
Waist circumference 1.21 (0.77-1.89) - 1.21 (0.73-1.99) - 0.79 (0.32-1.93) - 
Men  N=87,261  N=82,342  N=64,358  
Fasting blood glucose 0.92 (0.57-1.50)  0.75 (0.42-1.36)  0.87 (0.34-2.18)  
Blood pressure 2.59 (1.57-4.27) 2.73 (1.67-4.48) 2.76 (1.61-4.74) 2.88 (1.69-4.91) 1.61 (0.64-4.05) - 
Triglyceride 1.06 (0.66-1.70) - 0.99 (0.59-1.68) - 1.17 (0.53-2.58) - 
High-density lipoprotein cholesterol 0.98 (0.47-2.08) - 1.10 (0.49-2.46) - 2.01 (0.74-5.48) - 
Waist circumference 1.47 (0.91-2.37) - 1.42 (0.83-2.44) - 0.93 (0.37-2.34) - 
Women  N=67,299  N=65,266  N=57,488  
Fasting blood glucose 1.08 (0.37-3.18) 1.24 (0.43-3.56) 0.83 (0.23-3.04)  0.81 (0.10-6.78)  
Blood pressure 4.58 (1.62-12.92) 7.19 (2.81-18.42) 5.97 (1.99-17.87) 8.50 (3.17-22.75) 3.78 (0.72-19.78) 5.24 (1.08-25.52) 
Triglyceride 0.30 (0.07-1.36) - 0.39 (0.08-1.81) - - - 
High-density lipoprotein cholesterol 1.92 (0.71-5.17) - 1.82 (0.62-5.30) - 2.91 (0.71-11.84) - 
Waist circumference 0.39 (0.08-1.79) - 0.55 (0.12-2.61) - - - 
a Adjusted for age, sex, smoking status, alcohol intake, regular exercise 2 
HR, hazard ratio; CI, confidence interval; DM, diabetes mellitus; HTN, hypertension; CVD, cardiovascular disease 3 
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